ESC Heart Failure

Article	Citations
Heart failure after myocardial infarction: incidence and predictors	237
Detection of viral SARS‐CoV‐2 genomes and histopathological changes in endomyocardial biopsies	178
Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID‐19): autopsy reveals a ferroptosis signature	92
Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives	83
Machine learning vs. conventional statistical models for predicting heart failure readmission and mortality	83
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis	75
Left bundle branch area pacing delivery of cardiac resynchronization therapy and comparison with biventricular pacing	74
Echocardiographic abnormalities and predictors of mortality in hospitalized COVID‐19 patients: the ECHOVID‐19 study	73
Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock	68
Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic	66
Sarcopenia in heart failure: a systematic review and meta‐analysis	66
Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes	66
Anaemia, iron deficiency and heart failure in 2020: facts and numbers	61
Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus	59
Cardiogenic shock teams and centres: a contemporary review of multidisciplinary care for cardiogenic shock	50
Familial screening in case of acute myocarditis reveals inherited arrhythmogenic left ventricular cardiomyopathies	50
The detrimental effect of COVID‐19 nationwide quarantine on accelerometer‐assessed physical activity of heart failure patients	49
Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)	49
Heart failure in the last year: progress and perspective	48
Pulmonary artery catheter use in acute myocardial infarction‐cardiogenic shock	48
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data	47
Iron deficiency in heart failure	47
Motivational interviewing to improve self‐care in heart failure patients (MOTIVATE‐HF): a randomized controlled trial	47
Frailty and the risk of all‐cause mortality and hospitalization in chronic heart failure: a meta‐analysis	47
Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player	45

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials	44
Hospital readmissions of patients with heart failure from real world: timing and associated risk factors	44
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial	43
Effect of sacubitril/valsartan on renal function: a systematic review and meta‐analysis of randomized controlled trials	42
Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure	41
Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction	40
Delayed acute myocarditis and COVID‐19‐related multisystem inflammatory syndrome	38
Cardiac performance in patients hospitalized with COVID‐19: a 6 month follow‐up study	38
‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor	37
How to consider target heart rate in patients with systolic heart failure	35
Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors	35
Reaching consensus for unified medical language in Fontan care	34
A comprehensive individual patient data meta‐analysis of the effects of cardiac contractility modulation on functional capacity and heart failure‐related quality of life	34
Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic	34
Multi‐modality machine learning approach for risk stratification in heart failure with left ventricular ejection fraction ≤ 45%	34
Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction	34
Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes	33
Cognitive test results are associated with mortality and rehospitalization in heart failure: Swedish prospective cohort study	33
Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure	33
Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure	33
MitraClip and left ventricular reverse remodelling: a strain imaging study	32
Diagnosis of isolated cardiac sarcoidosis based on new guidelines	32
The role of B cells in heart failure and implications for future immunomodulatory treatment strategies	32
Prioritizing symptom management in the treatment of chronic heart failure	31
Multimarker approach including CRP, sST2 and GDF‐15 for prognostic stratification in stable heart failure	31
Myocardial injury in severe COVID‐19 is similar to pneumonias of other origin: results from a multicentre study	31
Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan	31
ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction	30
Compression therapy for leg oedema in patients with heart failure	30
Elevated plasma phenylalanine predicts mortality in critical patients with heart failure	30
Impact of lockdown on patients with congestive heart failure during the coronavirus disease 2019 pandemic	30
Heart failure is associated with an increased incidence of cancer diagnoses	29
Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction	29
Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry	29
Prognostic nutritional index in elderly patients hospitalized for acute heart failure	29
Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring	29
Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China	28
Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis	28
A year in heart failure: an update of recent findings	28
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial	28
Real‐world evidence in a national health service: results of the UK CardioMEMS HF System Post‐Market Study	28
Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients	27
Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions	27
Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction	26
Thromboembolism and bleeding in systemic amyloidosis: a review	26
Full spectrum of clonal haematopoiesis‐driver mutations in chronic heart failure and their associations with mortality	26
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	26
Advances in accelerometry for cardiovascular patients: a systematic review with practical recommendations	26
Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature	26
Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study	25

Implication of inhaled nitric oxide for the treatment of critically ill COVID‐19 patients with pulmonary hypertension	25
Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak	25
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis	25
Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines	25
Predictive value of H2FPEF score in patients with heart failure with preserved ejection fraction	25
Heart failure: an update from the last years and a look at the near future	25
Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial	25
Swollen heart in COVID‐19 patients who progress to critical illness: a perspective from echo‐cardiologists	25
Ethnic differences in association of outcomes with trimethylamine N‐oxide in acute heart failure patients	25
Racial disparities and outcomes of left ventricular assist device implantation as a bridge to heart transplantation	24
Meta‐analysis of echocardiographic quantification of left ventricular filling pressure	24
Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis	24
Race‐based and sex‐based differences in bioactive lipid mediators after myocardial infarction	24
Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry	24
In‐hospital and long‐term mortality for acute heart failure: analysis at the time of admission to the emergency department	24
Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT‐IHF randomized clinical trial	24
The impact of COVID‐19 on the management of heart failure: a United Kingdom patient questionnaire study	24
The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study	24
Diabetes mellitus and risk of new‐onset and recurrent heart failure: a systematic review and meta‐analysis	24
Age and shock severity predict mortality in cardiac intensive care unit patients with and without heart failure	23
Home‐based cardiac rehabilitation using information and communication technology for heart failure patients with frailty	23
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT	23
In‐hospital mortality in heart failure in Germany during the Covid‐19 pandemic	23
Blood urea nitrogen to serum albumin ratio as a new prognostic indicator in critical patients with chronic heart failure	23
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction	23
Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure	23
Cardiac adaptations to 60 day head‐down‐tilt bed rest deconditioning. Findings from the AGBRESA study	23
The impact of frailty according to Clinical Frailty Scale on clinical outcome in patients with heart failure	23
Non‐alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues	23
The prognostic value of serial troponin measurements in patients admitted for COVID‐19	23
Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials	23
Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients	22
Epidemiology of cardiogenic shock and cardiac arrest complicating non‐ST‐segment elevation myocardial infarction: 18‐year US study	22
Risk factors for myocardial injury in patients with coronavirus disease 2019 in China	22
A novel nomogram to predict all‐cause readmission or death risk in Chinese elderly patients with heart failure	22
Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy	22
6 min walk test is a strong independent predictor of death in outpatients with heart failure	22
Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis	22
Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction	22
Acute myocarditis after COVID‐19 vaccination with mRNA‐1273 in a patient with former SARS‐CoV‐2 infection	22
Applying the ESC 2016, H2FPEF, and HFA‐PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population	22
Prognostic impact of hospital‐acquired disability in elderly patients with heart failure	22
Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction	22
Clinical profile and midterm prognosis of left ventricular thrombus in heart failure	21
Cardiopoietic stem cell therapy in ischaemic heart failure: long‐term clinical outcomes	21
Intensity level and cardiorespiratory responses to Baduanjin exercise in patients with chronic heart failure	21
Impact of COVID‐19 on inpatient referral of acute heart failure: a single‐centre experience from the south‐west of the UK	21
Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction	21
Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction	21
Crosstalk between the activated Slit2–Robo1 pathway and TGF‐β1 signalling promotes cardiac fibrosis	21
Predicting sustained ventricular arrhythmias in dilated cardiomyopathy: a meta‐analysis and systematic review	21
Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis	21
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction	21
Smoking and heart failure: a Mendelian randomization and mediation analysis	21
The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta‐analysis	20
Insights into heart failure hospitalizations, management, and services during and beyond COVID‐19	20
DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure	20
Abnormal P‐wave terminal force in lead V1 is a marker for atrial electrical dysfunction but not structural remodelling	20
Copeptin as a predictive marker of incident heart failure	20
Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction	20
Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry	20
Iron deficiency in heart failure patients: the French CARENFER prospective study	20
Prognostic impact of Clinical Frailty Scale in patients with heart failure with preserved ejection fraction	20
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure	20
The effect of concomitant COVID‐19 infection on outcomes in patients hospitalized with heart failure	20
Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial	20
Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure	20
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems	20
Clinical presentation and long‐term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study	20
Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart F	20
What are the minimum requirements to establish proficiency in lung ultrasound training for quantifying B‐lines?	19
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage	19
Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT‐HF study	19
The role and molecular mechanism of FoxO1 in mediating cardiac hypertrophy	19
Prevalence and prognostic impact of cognitive frailty in elderly patients with heart failure: sub‐analysis of FRAGILE‐HF	19
Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial	19
Assessment of major mental disorders in a German peripartum cardiomyopathy cohort	19
Derivation of an electronic frailty index for predicting short‐term mortality in heart failure: a machine learning approach	19
A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance	19
Left ventricular midwall fibrosis as a predictor of sudden cardiac death in non‐ischaemic dilated cardiomyopathy: a meta‐analysis	19

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study	19
Role of climatic factors in the incidence of Takotsubo syndrome: A nationwide study from 2012 to 2016	19
Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype	19
Heart and kidney transplant: should they be combined or subsequent?	19
Myocardial work index: a marker of left ventricular contractility in pressure‐ or volume overload‐induced heart failure	19
Impact of telemedicine on the management of heart failure patients during coronavirus disease 2019 pandemic	19
Metabolomic signatures of cardiac remodelling and heart failure risk in the community	19
Identification of novel circulating microRNAs in advanced heart failure by next‐generation sequencing	19
Echocardiographic assessment of insulin‐like growth factor binding protein‐7 and early identification of acute heart failure	19
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial	19
Admission NT‐proBNP and outcomes in patients without history of heart failure hospitalized with COVID‐19	19
Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants	18
Pathophysiological role of fatty acid‐binding protein 4 in Asian patients with heart failure and preserved ejection fraction	18
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison	18
Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta‐regression analysis	18
Comparison of different prediction models for the indication of implanted cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy	18
ESC EORP Cardiomyopathy Registry: real‐life practice of genetic counselling and testing in adult cardiomyopathy patients	18
Impact analysis of heart failure across European countries: an ESC‐HFA position paper	18
High‐sensitivity cardiac troponin T determines all‐cause mortality in cancer patients: a single‐centre cohort study	18
Non‐invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta‐analysis	18
The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study	18
One‐year results following PASCAL‐based or MitraClip‐based mitral valve transcatheter edge‐to‐edge repair	18
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension	18
Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation	18
Late phase of COVID‐19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice	18
Current patterns of beta‐blocker prescription in cardiac amyloidosis: an Italian nationwide survey	18
Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users	18
Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction	18
Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure	18
Late gadolinium enhancement characteristics in giant cell myocarditis	18
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry	18
Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure	18
MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally induced cardiomyopathies	18
Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type	17
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report	17
Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series	17
Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series	17
Propensity score‐based analysis of long‐term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support	17
Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction	17
Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016	17
The oral Ca/calmodulin‐dependent kinase II inhibitor RA608 improves contractile function and prevents arrhythmias in heart failure	17
Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis	17
Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction	17
Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence	17
Ryanodine receptor and immune‐related molecules in diabetic cardiomyopathy	17
Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF	17
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT	17
A case series analysis on the clinical experience of Impella 5.5® at a large tertiary care centre	17
Growth differentiation factor 15 as mortality predictor in heart failure patients with non‐reduced ejection fraction	17
Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation	17
Impact of COVID‐19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV‐HF‐SIRIO 6 study)	17
Individual patient data meta‐analysis of the effects of the CARILLON® mitral contour system	17
Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery	17
Long‐term impact of new‐onset atrial fibrillation complicating acute myocardial infarction on heart failure	17
Heart failure with preserved, mid‐range, and reduced ejection fraction across health care settings: an observational study	17
Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment	17
99mTechnetium‐pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy	17
Fatality rates and use of systemic thrombolysis in pregnant women with pulmonary embolism	17
Prognostic factors of Takotsubo cardiomyopathy: a systematic review	17
Subclinical cardiac dysfunction in obesity patients is linked to autonomic dysfunction: findings from the CARDIOBESE study	17
Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure	17
Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications	17
Prevalence and prognostic value of the coexistence of anaemia and frailty in older patients with heart failure	17
Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry	17
Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing	17
The effect of high‐flow arteriovenous fistulas on systemic haemodynamics and brain oxygenation	16
Monozygotic twins with myocarditis and a novel likely pathogenic desmoplakin gene variant	16
Gateway and journey of patients with cardiac amyloidosis	16
Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial	16
Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice	16
Outflow graft obstruction after left ventricular assist device implantation: a retrospective, single‐centre case series	16
Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy‐tailored prognostic model	16
A global longitudinal strain cut‐off value to predict adverse outcomes in individuals with a normal ejection fraction	16
Prognostic impact of nutritional status and physical capacity in elderly patients with acute decompensated heart failure	16
ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction	16
Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge	16
Sex differences in patients with cardiogenic shock	16
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program	16
Effects of the COVID‐19 pandemic on heart failure hospitalizations in Japan: interrupted time series analysis	16
Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink	16
Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction	16
Use of extracorporeal circulation (ECLS/ECMO) for cardiac and circulatory failure –A clinical practice Guideline Level 3	16
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload	16
Endothelial dysfunction and C‐reactive protein predict the incidence of heart failure in hypertensive patients	16
Time‐sensitive approach in the management of acute heart failure	16
Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence	15
Sudden cardiogenic shock mimicking fulminant myocarditis in a surviving teenager affected by severe acute respiratory syndrome coronavirus 2 infection	15
Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism	15
Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective	15
Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure	15
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	15
Diabetes mellitus exacerbates post‐myocardial infarction heart failure by reducing sarcolipin promoter methylation	15
High‐protein vs. standard‐protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro‐HEART trial	15
Hypocalcaemic cardiomyopathy: a description of two cases and a literature review	15
Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure	15